`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Inventor:
`
`PAPADOPOULOS et al.
`
`Title:
`
`Modified Chimeric Polypeptides with Improved Pharmacokinetic
`Properties
`
`Appl. No.:
`
`10/009,852
`
`§371 Date:
`
`December6, 2001
`
`Patent No.:
`
`7,070,959
`
`Grant Date:
`
`July 4, 2006
`
`Assignee:
`
`Product:
`
`Regeneron Pharmaceuticals, Inc.
`
`EYLEA®(aflibercept)
`
`ELECTION IN ACCORDANCE WITH 37 C.F.R. § 1.785(b)
`
`via EFS WEB
`Mail Stop Hatch-Waxman PTE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`This communication is in response to the Notice of Final Determination and Requirement
`
`for Election ("Notice"), dated March 17, 2016, for the captioned patent. The Notice provided
`
`Applicant with an opportunity in accordance with 37 C.F.R. §1.785(b) to elect U.S. 7,070,959,
`
`U.S. 7,374,757, or U.S. 7,374,758 for patent term extension under 35 U.S.C. §156.
`
`Applicant hereby elects U.S.7,070,959 for patent term extension. Thus, Applicant
`
`respectfully requests a certificate of extension be issued for U.S. 7,070,959 for a period of 1,119
`days, as indicated in the Notice, such that the expiration date of the extension is June 16, 2023.
`
`This election is timely becauseit is being filed by the April 17, 2016 due date set forth in the
`
`Notice.
`
`Mylan Exhibit 1127
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Mylan Exhibit 1127
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`
`
`Nofee is believed to be due with this election. However, in the event a fee is required,
`
`the Commissioneris hereby authorized to charge any such fee to Deposit Account No. 18-0650.
`
`Atty. Docket No. 0710A
`
`Dated: April 5, 2016
`
`Respectfully submitted,
`
`By / Frank R. Cottingham /
`
`Frank R. Cottingham
`Attorney for Applicant
`Reg. No. 50,437
`Regeneron Pharmaceuticals, Inc.
`Customer Number: 26693
`777 Old Saw Mill River Road
`Tarrytown, NY 10591
`Direct Tel.: (914) 847-1116
`
`Mylan Exhibit 1127
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`Mylan Exhibit 1127
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`